Summary
Fifteen patients with active rheumatoid arthritis who had not previously received oral corticosteroids were recruited into an open study using the Leeds Human Model Screening System to assess whether prednisolone has any activity as a second-line agent. The daily dose of prednisolone was 10 mg/day, and all patients completed the full study duration of 24 weeks, with only one patient requiring a dose reduction to 7.5 mg. Patients were then recruited into a further open study during which dosage reduction of 1 mg/month was attempted. Patients were assessed using six clinical and six laboratory variables, and statistically significant improvement (P<0.01) was seen in seven of 12 variables at 24 weeks. After 48 weeks, two variables showed statistically significant improvement at P<0.01, with improvement in a further four variables significant at P<0.05. This degree of change ranks prednisolone below established second-line agents such as sodium aurothiomalate and d-penicillamine but ahead of non-steroidal anti-inflammatory drugs, suggesting that in addition to their known anti-inflammatory properties corticosteroids may have some action as second-line agents.
Similar content being viewed by others
References
Hench PS, Kendall EC, Slocumb CH, et al (1949) The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: compound E) and of pituitary adrenocorticotrophic hormone on rheumatoid arthritis: preliminary report. Proc Staff Meet Mayo Clin 24: 181–197
Joint Committee of the Medical Research Council and Nuffield Foundation (1955). A comparison of cortisone and aspirin in the treatment of early cases of rheumatoid arthritis. Br Med J 2:695–700
Lipsky PE (1987) Rheumatoid arthritis. In: Braunwald E, Isselbacker KJ, Petersdorf RG, et al. (eds) Harrison's principles of internal medicine. McGraw-Hill, New York, pp 1423–1428
Ruddy S (1985) The management of rheumatoid arthritis. In: Kelley WN, Harris ED Jr, Ruddy S, et al (eds) Textbook of rheumatology. Saunders, Philadelphia, 979–992
Joint Committee of the Medical Research Council and the Nuffield Foundation (1959) A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. Ann Rheum Dis 18:173–188
Joint Committee of the Medical Research Council and Nuffield Foundation (1960) A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. Ann Rheum Dis 19:331–337
Harris ED, Emkey RD, Nichols JE, Newberg A (1983) Low-dose prednisone therapy in rheumatoid arthritis: a double blind study. J Rheumatol 10:713–721
Buchanan WW, Stephen LJ, Buchanan HM (1988) Are “homeopathic” doses of oral corticosteroids effective in rheumatoid arthritis? Clin Exp Rheumatol 6:281–284
de Andrade JR, McCormick JN, Hill AGS (1964) Small doses of prednisolone in the management of rheumatoid arthritis. Ann Rheum Dis 23:158–162
Ramos-Remus C, Sibley J, Russell AS (1992) Steroids in rheumatoid arthritis: the honeymoon revisited. J Rheumatol 19:667–670
Masi AT (1983) Low dose glucocorticoid therapy in rheumatoid arthritis (RA): transitional or selected add-on therapy? J Rheumatol 10:675–678
Weiss MM (1989) Corticosteroids in rheumatoid arthritis. Semin Arthritis Rheum 19(1):9–21
Byron MA, Kirwan JR (1986) Corticosteroids in rheumatoid arthritis: is a trial of their ‘disease modifying’ potential feasible? Ann Rheum Dis 46:171–173
Dixon JS, Bird HA, Pickup ME, Wright V (1982) A human model screening system for the detection of specific antirheumatic activity. Semin Arthritis Rheum 12:185–190
Dixon JS (1982) Biochemical and clinical changes in rheumatoid arthritis: their relation to the action of anti-rheumatic drugs. Semin Arthritis Rheum 12:191–207
Bird HA, Dixon JS, Pickup ME, Rhind VM, Lowe JR, Lee MR, Wright V (1982) A biochemical assessment of sulphasalazine in rheumatoid arthritis. J Rheumatol 9:36–45
Neumann VC, Grindulis KA, Hubball S, McConkey B, Wright V (1983) Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial. Br Med J 287:1099–1102
Dixon JS (1981) Biochemical and clinical changes in rheumatoid arthritis: their relation to the action of anti-rheumatic drugs. PhD Thesis, University of Leeds
Dawes PT, Fowler PD, Clarke S, Fisher J, Lawton A, Shadforth MF (1986) Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression. Br J Rheumatol 25:44–49
Miesfield RL (1990) Molecular genetics of corticosteroid action. Am Rev Respir Dis 141:S11-S17
Cooper C, Kirwan JR (1990) The risks of local and systemic corticosteroid administration. In Bailliere's Clin Rheumat 4(3):305–332
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tait, T.J., Le Gallez, P., Astbury, C. et al. A clinical and biochemical evaluation of prednisolone in patients with active rheumatoid arthritis. Rheumatol Int 13, 241–245 (1994). https://doi.org/10.1007/BF00290202
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00290202